Equities research analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce ($1.32) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings. The lowest EPS estimate is ($1.44) and the highest is ($1.19). Ascendis Pharma A/S reported earnings of ($0.66) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 100%. The company is expected to report its next quarterly earnings report on Wednesday, September 4th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year earnings of ($5.46) per share for the current financial year, with EPS estimates ranging from ($5.93) to ($4.88). For the next year, analysts expect that the firm will report earnings of ($5.16) per share, with EPS estimates ranging from ($7.39) to ($1.64). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.44). Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. The firm had revenue of $6.15 million for the quarter, compared to analyst estimates of $0.66 million.
A number of equities analysts have weighed in on ASND shares. Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Monday, June 10th. Canaccord Genuity upped their price objective on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Wedbush reiterated a “buy” rating and set a $223.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. Finally, BidaskClub cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $137.22.
NASDAQ:ASND traded down $7.23 during trading hours on Monday, reaching $109.12. 653,133 shares of the stock were exchanged, compared to its average volume of 215,417. Ascendis Pharma A/S has a twelve month low of $53.21 and a twelve month high of $133.96. The company has a current ratio of 22.32, a quick ratio of 22.32 and a debt-to-equity ratio of 0.02. The company’s 50 day simple moving average is $116.27. The stock has a market capitalization of $4.81 billion, a PE ratio of -29.18 and a beta of 0.62.
A number of hedge funds have recently bought and sold shares of the business. Aperio Group LLC increased its position in Ascendis Pharma A/S by 3.3% during the 2nd quarter. Aperio Group LLC now owns 4,582 shares of the biotechnology company’s stock worth $528,000 after buying an additional 147 shares during the period. Comerica Bank increased its position in Ascendis Pharma A/S by 7.8% during the 2nd quarter. Comerica Bank now owns 2,460 shares of the biotechnology company’s stock worth $277,000 after buying an additional 179 shares during the period. SG Americas Securities LLC increased its position in Ascendis Pharma A/S by 12.6% during the 1st quarter. SG Americas Securities LLC now owns 2,088 shares of the biotechnology company’s stock worth $246,000 after buying an additional 234 shares during the period. NumerixS Investment Technologies Inc acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $94,000. Finally, Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $113,000.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: Do stock splits help investors?
Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.